Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with
many unique properties such as small size, excellent solubility, superior stability, quick …

In spite of the successful use of monoclonal antibodies (mAbs) in clinic for tumor treatment,
their applications are still hampered in therapeutic development due to limitations, such as …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

Camelidae derived single-domain antibodies (sdAbs), commonly known as nanobodies
(Nbs), are the smallest antibody fragments with full antigen-binding capacity. Owing to their …

Antibodies have long been recognised as potent vectors for carrying diagnostic medical
radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of …

Molecular imaging is paving the way towards noninvasive detection, staging, and treatment
follow-up of diseases such as cancer and inflammation-related conditions. Monoclonal …

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …

Monoclonal antibodies and their fragments have significantly changed the outcome of
cancer in the clinic, effectively inhibiting tumor cell proliferation, triggering antibody …